Epstein-Barr virus antibodies and the risk of associated malignancies: Review of the literature

American Journal of Epidemiology

Volumn 180, Issue 7, 2014, Pages 687-695

  Coghill, Anna E ^a   Hildesheim, Allan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Burkitt lymphoma; EBV antibodies; EBV immune response; EBV serology; gastric carcinoma; Hodgkin lymphoma; nasopharyngeal carcinoma; non Hodgkin lymphoma

Indexed keywords

EPSTEIN BARR VIRUS ANTIBODY; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN A;

ANTIBODY; DISEASE SEVERITY; IMMUNE RESPONSE; INFECTIOUS DISEASE; LITERATURE REVIEW; SAMPLING; TUMOR; VIRUS;

ANTIBODY TITER; BURKITT LYMPHOMA; CANCER RISK; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SAMPLE SIZE; STOMACH CARCINOMA; BLOOD; IMMUNOLOGY; LYMPHOMA; NASOPHARYNX TUMOR; RISK FACTOR; STOMACH TUMOR; VIROLOGY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

ANTIBODIES, VIRAL; BIOMARKERS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LYMPHOMA; NASOPHARYNGEAL NEOPLASMS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84921463170     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwu176     Document Type: Review

References (75)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000; 343(7):481-492.
2. Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol. 2000;34(1):27-53.
3. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4(10):757-768.
4. Babcock GJ, Decker LL, Volk M, et al. EBV persistence in memory B cells in vivo. Immunity. 1998;9(3):395-404.
5. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol. 2000;165(6):2975-2981.
6. de-Thé G, Day NE, Geser A, et al. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study-a review. IARC Sci Publ. 1975;(11 Pt 2):3-16.
7. Dowd JB, Palermo T, Brite J, et al. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One. 2013;8(5):e64921.
8. Cao SM, Liu Z, Jia WH, et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One. 2011;6(4):e19100.
9. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345(26):1877-1882.
10. Ji MF, Wang DK, Yu YL, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer. 2007;96(4): 623-630.
11. Yu KJ, Hsu WL, Pfeiffer RM, et al. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res. 2011;17(7):1906-1914.
12. Hildesheim A. Invited commentary: Epstein-Barr virusbased screening for the early detection of nasopharyngeal carcinoma: a new frontier. Am J Epidemiol. 2013;177(3): 251-253.
13. Liu Z, Ji MF, Huang QH, et al. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am J Epidemiol. 2013; 177(3):242-250.
14. Janeway C. Immunobiology. 7th ed. New York, NY: Garland Science, Taylor & Francis Group; 2008.
15. Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995; 333(11):693-698.
16. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol. 2002;12(6):431-441.
17. Niedobitek G, Agathanggelou A, Nicholls JM. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol. 1996;7(4): 165-174.
18. Vera-Sempere FJ, Burgos JS, Botella MS, et al. Immunohistochemical expression of Epstein-Barr virusencoded latent membrane protein (LMP-1) in paraffin sections of EBV-associated nasopharyngeal carcinoma in Spanish patients. Eur J Cancer B Oral Oncol. 1996;32B(3): 163-168.
19. Brooks L, Yao QY, Rickinson AB, et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol. 1992;66(5):2689-2697.
20. Fåhraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988;42(3):329-338.
21. Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virusinfected neoplasia. Am J Pathol. 1995;146(6):1355-1367.
22. de-The G, Lavoue MF, Muenz L. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas. IARC Sci Publ. 1978;(20):471-481.
23. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976;17(1):1-7.
24. Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev. 1993;15(2):466-485.
25. Lanier A, Bender T, Talbot M, et al. Nasopharyngeal carcinoma in Alaskan Eskimos Indians, and Aleuts: a review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. Cancer. 1980;46(9):2100-2106.
26. Lanier AP, Bornkamm GW, Henle W, et al. Association of Epstein-Barr virus with nasopharyngeal carcinoma in Alaskan native patients: serum antibodies and tissue EBNA and DNA. Int J Cancer. 1981;28(3):301-305.
27. Lanier AP, Henle W, Bender TR, et al. Epstein-Barr virus-specific antibody titers in seven Alaskan natives before and after diagnosis of nasopharyngeal carcinoma. Int J Cancer. 1980;26(2):133-137.
28. Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824-833.
29. Kim Y, Shin A, Gwack J, et al. Epstein-Barr virus antibody level and gastric cancer risk in Korea: a nested case-control study. Br J Cancer. 2009;101(3):526-529.
30. Koshiol J, Qiao YL, Mark SD, et al. Epstein-Barr virus serology and gastric cancer incidence and survival. Br J Cancer. 2007; 97(11):1567-1569.
31. Levine PH, Stemmermann G, Lennette ET, et al. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. Int J Cancer. 1995;60(5):642-644.
32. Shinkura R, Yamamoto N, Koriyama C, et al. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan. J Med Virol. 2000; 60(4):411-416.
33. Schetter AJ, You WC, Lennette ET, et al. Association of Epstein-Barr virus antibody levels with precancerous gastric lesions in a high-risk cohort. Cancer Sci. 2008;99(2):350-354.
34. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol. 1991;13(2):222-246.
35. de-Thé G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978; 274(5673):756-761.
36. Geser A, de Thé G, Lenoir G, et al. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int J Cancer. 1982;29(4): 397-400.
37. Asito AS, Piriou E, Odada PS, et al. Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infect Agent Cancer. 2010;5:13.
38. Carpenter LM, Newton R, Casabonne D, et al. Antibodies against malaria and Epstein-Barr virus in childhood Burkitt lymphoma: a case-control study in Uganda. Int J Cancer. 2008; 122(6):1319-1323.
39. Mutalima N, Molyneux E, Jaffe H, et al. Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One. 2008;3(6):e2505.
40. Hochberg FH, Miller G, Schooley RT, et al. Centralnervous-system lymphoma related to Epstein-Barr virus. N Engl J Med. 1983;309(13):745-748.
41. Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335(8682):128-130.
42. Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988;318(12): 733-741.
43. Carbone A. AIDS-related non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol. 2002;33(4):392-404.
44. Carbone A, Cesarman E, Spina M, et al. HIV-associated lymphomas and gamma-herpesviruses. Blood. 2009;113(6): 1213-1224.
45. Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993;82(2):619-624.
46. MacMahon E, Glass D, Hayward D, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet. 1991;338(8773):969-973.
47. Shibata D, Weiss LM, Hernandez AM, et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 1993;81(8): 2102-2109.
48. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. Aids. 2000; 14(2):133-140.
49. Moir S, Fauci AS. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol. 2008; 122(1):12-19.
50. Purdue MP, Lan Q, Bagni R, et al. Prediagnostic serum levels of cytokines and other immune markers and risk of non-Hodgkin lymphoma. Cancer Res. 2011;71(14): 4898-4907.
51. Breen EC, Hussain SK, Magpantay L, et al. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1303-1314.
52. Lehtinen T, Lumio J, Dillner J, et al. Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies-a prospective study. Cancer Causes Control. 1993;4(3): 187-193.
53. Mueller N, Mohar A, Evans A, et al. Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma. Int J Cancer. 1991;49(3):387-393.
54. Hardell E, Eriksson M, Lindström G, et al. Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma. Leuk Lymphoma. 2001;42(4): 619-629.
55. Bertrand KA, Birmann BM, Chang ET, et al. A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma. Blood. 2010;116(18):3547-3553.
56. Richiardi L, De Marco L, Gillio-Tos A, et al. Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin's lymphoma. Cancer Epidemiol. 2010;34(6):709-712.
57. Rothman N, Cantor KP, Blair A, et al. A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues. Lancet. 1997;350(9073):240-244.
58. Hardell K, Carlberg M, Hardell L, et al. Concentrations of organohalogen compounds and titres of antibodies to Epstein-Barr virus antigens and the risk for non-Hodgkin lymphoma. Oncol Rep. 2009;21(6):1567-1576.
59. De Roos AJ, Martinez-Maza O, Jerome KR, et al. Investigation of Epstein-Barr virus as a potential cause of B-cell non-Hodgkin lymphoma in a prospective cohort. Cancer Epidemiol Biomarkers Prev. 2013;22(10):1747-1755.
60. de Sanjosé S, Bosch R, Schouten T, et al. Epstein-Barr virus infection and risk of lymphoma: immunoblot analysis of antibody responses against EBV-related proteins in a large series of lymphoma subjects and matched controls. Int J Cancer. 2007;121(8):1806-1812.
61. Evans AS, Gutensohn NM. A population-based case-control study of EBV and other viral antibodies among persons with Hodgkin's disease and their siblings. Int J Cancer. 1984;34(2): 149-157.
62. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virusassociated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer. 1997;70(4):375-382.
63. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol. 1995; 13(7):1758-1767.
64. Ambinder RF. Epstein-Barr virus and Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2007:204-209.
65. Levin LI, Chang ET, Ambinder RF, et al. Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. Blood. 2012;120(18):3750-3755.
66. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. N Engl J Med. 1989;320(11):689-695.
67. Mueller NE, Lennette ET, Dupnik K, et al. Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis. Int J Cancer. 2012; 130(12):2886-2891.
68. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A. 1987;84(2):570-574.
69. Rickinson ABKE. Epstein-Barr Virus. Vol 2. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
70. Zheng D, Wan J, Cho YG, et al. Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcomaassociated herpesvirus using a viral proteome microarray. J Infect Dis. 2011;204(11):1683-1691.
71. Gu AD, Lu LX, Xie YB, et al. Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology. J Transl Med. 2009;7:73.
72. Zeng Y, Zhang LG, Li HY, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer. 1982;29(2):139-141.
73. Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer. 1985;36(5):545-547.
74. Zeng Y, Zhong JM, Li LY, et al. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology. 1983;20(4):190-194.
75. Zong YS, Sham JS, Ng MH, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer. 1992;69(1):3-7.